# US 2021/0261604 A1 · Compositions for active immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261604 A1
- Document ID: US20210261604A1
- Status: Published application
- Kind: A1
- Application number: 17/078,883
- Filed: 2019-04-26
- Published: 2021-08-26
- Earliest claimed: 2018-04-26
- Assignees: Vib Vzw; Universiteit Gent
- Applicants: Vib Vzw; Universiteit Gent
- Inventors: Nico Callewaert; Charlot De Wachter
- Web page: https://patentgrep.com/patent/US20210261604A1

## CPC

- A61K 39/35: Allergens
- C07K 1/122: {Hydrolysis with acids different from HF}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/43531: {from mites}
- C12N 9/641: {Cysteine endopeptidases (3.4.22)}
- C12Y 304/22065: Peptidase 1 (mite) (3.4.22.65)
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides to novel prophylactic and therapeutic formulations being effective in the prevention and/or the reduction of allergenic responses to specific allergens. In particular the invention provides compositions comprising deglycosylated allergens which allergens are normally glycosylated in their natural environment. Further this invention further relates to hypoallergenic recombinant deglycosylated derivatives of the major protein allergen from Dermatophagoides pteronyssinus, allergen proDerp1. Even more particularly the invention further provides hypoallergenic recombinant deglycosylated derivatives of proDerp1 of which catalytic cysteine 132 is mutated.

## Claims

### Claim 1

A method of producing a composition, the method comprising:
alkylating a recombinant protein comprising SEQ ID NO: 1 (proDerp1) at the thiol group of the cysteine at position 132 of SEQ ID NO: 1; and
enzymatically deglycosylating the thio-alkylated recombinant protein with an enzyme specific for N-glycans.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising producing the recombinant protein in a recombinant fungal or yeast cell.

### Claim at position 3

3-10. (canceled)

### Claim 11 (depends on 1)

A composition comprising the alkylated and deglycosylated recombinant protein produced by the method of claim 1.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the composition is a pharmaceutical composition and where the composition further comprises a pharmaceutical excipient.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the composition further comprises an adjuvant.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the adjuvant is a Th1-inducing adjuvant.

### Claim 15 (depends on 11)

A method of active immunotherapy, the method comprising administering to a mammalian subject the composition of claim 11.
